NO965621L - Nye hIL-4-mutantproteiner som antagonister eller partielle agonister for det humane interleukin 4 - Google Patents

Nye hIL-4-mutantproteiner som antagonister eller partielle agonister for det humane interleukin 4

Info

Publication number
NO965621L
NO965621L NO965621A NO965621A NO965621L NO 965621 L NO965621 L NO 965621L NO 965621 A NO965621 A NO 965621A NO 965621 A NO965621 A NO 965621A NO 965621 L NO965621 L NO 965621L
Authority
NO
Norway
Prior art keywords
mutant proteins
pct
antagonists
human interleukin
partial agonists
Prior art date
Application number
NO965621A
Other languages
English (en)
Other versions
NO965621D0 (no
Inventor
Hanno Wild
Rudolf Hanko
Michael Doerschug
Hans-Dietrich Hoerlein
Juergen Beunink
Heiner Apeler
Hermann Wehlmann
Walter Sebald
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of NO965621L publication Critical patent/NO965621L/no
Publication of NO965621D0 publication Critical patent/NO965621D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Det blir beskrevet hIL-4-mutantproteiner, fremgangsmåter for fremstilling av dem og deres anvendelse som medikamenter, spesielt for behandling av overskudds, feilregu-lerte immunoreaksjoner og autoimmune sykdommer.
NO965621A 1994-07-01 1996-12-30 Nye hIL-4-mutantproteiner som antagonister eller partielle agonister for det humane interleukin 4 NO965621D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4423131A DE4423131A1 (de) 1994-07-01 1994-07-01 Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
PCT/EP1995/002358 WO1996001274A1 (de) 1994-07-01 1995-06-19 NEUE hIL-4-MUTANTENPROTEINE ALS ANTAGONISTEN ODER PARTIELLE AGONISTEN DES HUMANEN INTERLEUKIN 4

Publications (2)

Publication Number Publication Date
NO965621L true NO965621L (no) 1996-12-30
NO965621D0 NO965621D0 (no) 1996-12-30

Family

ID=6522032

Family Applications (1)

Application Number Title Priority Date Filing Date
NO965621A NO965621D0 (no) 1994-07-01 1996-12-30 Nye hIL-4-mutantproteiner som antagonister eller partielle agonister for det humane interleukin 4

Country Status (18)

Country Link
US (1) US6130318A (no)
EP (1) EP0769020B1 (no)
JP (3) JPH10502360A (no)
KR (1) KR100393508B1 (no)
AT (1) ATE190068T1 (no)
AU (1) AU705745B2 (no)
CA (1) CA2193993C (no)
CZ (1) CZ292703B6 (no)
DE (2) DE4423131A1 (no)
DK (1) DK0769020T3 (no)
ES (1) ES2145280T3 (no)
GR (1) GR3033498T3 (no)
HU (1) HU221416B1 (no)
NO (1) NO965621D0 (no)
SK (1) SK284391B6 (no)
TW (1) TW458984B (no)
WO (1) WO1996001274A1 (no)
ZA (1) ZA955443B (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9415379D0 (en) * 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
WO1999025732A2 (en) * 1997-11-13 1999-05-27 Europäisches Laboratorium für Molekularbiologie (EMBL) Design of coiled-coil dimer derived antagonists of 4-helix bundle cytokine specific receptors
ATE498409T1 (de) 1998-08-06 2011-03-15 Mountain View Pharmaceuticals Peg-uricase konjugate und verwendung davon
DE02800437T1 (de) 2001-10-03 2004-11-11 The President And Fellows Of Harvard College, Cambridge Copolymere zur unterdrückung von autoimmunkrankheiten und anwendungsverfahren
ATE531447T1 (de) * 2003-01-17 2011-11-15 Cornell Res Foundation Inc Injizierbare hydrogel-microsphären aus wässrigem zwei-phasen-system
US7785580B2 (en) * 2003-08-29 2010-08-31 Aerovance, Inc. Modified IL-4 mutein receptor antagonists
RU2389796C2 (ru) * 2003-08-29 2010-05-20 Аэровэнс, Инк. Модифицированный антагонист рецептора il-4 и предназначенный для его получения очищенный полинуклеотид
US7404957B2 (en) * 2003-08-29 2008-07-29 Aerovance, Inc. Modified IL-4 mutein receptor antagonists
ZA200601759B (en) * 2003-08-29 2007-04-25 Bayer Pharmaceuticals Corp Modified IL-4 mutein receptor antagonists
US7635754B2 (en) * 2004-09-22 2009-12-22 Aerovance, Inc. Interleukin-9 and interleukin-4 chimeric antagonist muteins and methods of using same
WO2006079169A1 (en) * 2005-01-25 2006-08-03 Apollo Life Sciences Limited Parameter selected gm-csf, il-3, il-4, il-5 and chimeras thereof for therapeutic and diagnostic purposes
SG161247A1 (en) * 2005-04-11 2010-05-27 Savient Pharmaceuticals Inc Variant forms of urate oxidase and use thereof
MX2007012548A (es) * 2005-04-11 2008-03-11 Savient Pharmaceuticals Inc Formas variantes de urato oxidasa y uso de las mismas.
US20070009479A1 (en) * 2005-06-17 2007-01-11 Aerovance, Inc. Methods for treating dermatitis using mutant human IL-4 compositions
JP2009525267A (ja) * 2006-01-11 2009-07-09 アエロヴァンス インコーポレイティッド ヒトおよび非ヒト霊長類において喘息を処置するための方法および組成物
WO2007147600A2 (en) * 2006-06-21 2007-12-27 Apogenix Gmbh Differential il-4 and/or il-10 cytokine expression in human cancer
US20100086515A1 (en) * 2006-07-06 2010-04-08 Apogenix Gmbh Human il-4 muteins in cancer therapy
WO2008101671A2 (en) * 2007-02-19 2008-08-28 Apogenix Gmbh Il-4 fc fusion proteins
KR20100047866A (ko) * 2007-07-11 2010-05-10 애로반스, 인코포레이티드 약제학적 폴리펩타이드 건조 분말 에어로졸 제형 및 이의 제조 방법
JP2009217498A (ja) * 2008-03-10 2009-09-24 Sato Knowledge & Intellectual Property Institute 印字試験システム
US8182626B2 (en) 2008-10-30 2012-05-22 Continental Ag Tire composition with improved vulcanizing agent
US9377454B2 (en) 2009-06-25 2016-06-28 Crealta Pharmaceuticals Llc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
EP2850093B1 (en) 2012-01-27 2019-01-09 The Board of Trustees of the Leland Stanford Junior University Therapeutic il-13 polypeptides
CN104619334A (zh) 2012-08-09 2015-05-13 利兰斯坦福初级大学董事会 超级因子和合成因子:具有新的和增强的信号传导活性的经改造细胞因子
EP2813242A1 (en) * 2013-06-13 2014-12-17 PLS-Design GmbH Low molecular weight immune-modulators as adjuvants for specific immunotherapy
EP3049526B1 (en) 2013-09-24 2021-02-24 Medicenna Therapeutics, Inc. Interleukin-4 receptor-binding fusion proteins and uses thereof
CN116637177A (zh) 2016-11-11 2023-08-25 好利恩治疗美国公司 泼尼松和尿酸酶分子的组合疗法及其用途
EP3694558B1 (en) 2017-10-10 2024-04-10 Medicenna Therapeutics Inc. Il-4-fusion formulations for treatment of central nervous system (cns) tumors
WO2019239213A2 (en) 2018-06-01 2019-12-19 Medicenna Therapeutics Inc. Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof
US12590133B2 (en) 2018-06-01 2026-03-31 The Board Of Trustees Of The Leland Stanford Junior University IL-13/IL-4 superkines: immune cell targeting constructs and methods of use thereof
WO2020160322A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Tolerization reduces intolerance to pegloticase and prolongs the urate lowering effect (triple)
WO2020160325A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
CN112538108B (zh) * 2020-12-24 2022-06-28 郑州大学 高亲和pvr突变体
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) * 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) * 1979-07-11 1985-06-05 味の素株式会社 代用血液
DE3169595D1 (en) * 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
US4485045A (en) * 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
DE3374837D1 (en) * 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
DE3218121A1 (de) * 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) * 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) * 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3336583A1 (de) * 1983-09-26 1985-04-25 Udo Dr. 8400 Regensburg Ehrenfeld Erzeugnis zur diagnose und therapie von malignen tumoren
DE3474511D1 (en) * 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) * 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
WO1987005330A1 (en) * 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
WO1988004667A1 (en) * 1986-12-19 1988-06-30 Immunex Corporation Human interleukin-4 muteins
JPH02501827A (ja) * 1986-12-19 1990-06-21 イミュネックス・コーポレーション ヒト・インターロイキン‐４　ミューテイン
PT88641B (pt) * 1987-10-02 1993-04-30 Genentech Inc Metodo para a preparacao de uma variante de adesao
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5538884A (en) * 1991-05-02 1996-07-23 Novo Nordisk A/S Rhamnogalacturonase, corresponding DNA sequence, rhamnogalacturonase containing enzyme preparation and use of the enzyme preparation
DE4137333A1 (de) * 1991-11-13 1993-05-19 W Prof Dr Sebald Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung
US5298410A (en) * 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life

Also Published As

Publication number Publication date
SK284391B6 (sk) 2005-03-04
DE4423131A1 (de) 1996-01-04
DE59507920D1 (de) 2000-04-06
CZ384896A3 (en) 1997-06-11
EP0769020B1 (de) 2000-03-01
KR100393508B1 (ko) 2003-10-23
ES2145280T3 (es) 2000-07-01
ATE190068T1 (de) 2000-03-15
US6130318A (en) 2000-10-10
WO1996001274A1 (de) 1996-01-18
SK169296A3 (en) 1997-08-06
HU9603563D0 (en) 1997-02-28
ZA955443B (en) 1996-02-13
AU2885295A (en) 1996-01-25
DK0769020T3 (da) 2000-07-31
CA2193993A1 (en) 1996-01-18
HU221416B1 (en) 2002-09-28
AU705745B2 (en) 1999-06-03
EP0769020A1 (de) 1997-04-23
CA2193993C (en) 2008-11-18
JPH10502360A (ja) 1998-03-03
GR3033498T3 (en) 2000-09-29
HUT77577A (hu) 1998-06-29
JP2011102302A (ja) 2011-05-26
JP2007051161A (ja) 2007-03-01
TW458984B (en) 2001-10-11
NO965621D0 (no) 1996-12-30
CZ292703B6 (cs) 2003-11-12

Similar Documents

Publication Publication Date Title
NO965621L (no) Nye hIL-4-mutantproteiner som antagonister eller partielle agonister for det humane interleukin 4
ATE182623T1 (de) Humanes serum albumin, herstellung und verwendung
DE69324671D1 (de) Verbesserte alpha-interferon-zusammensetzung und verfahren zu ihrer herstellung aus leukocyten des menschlichen peripheren blute
PT822199E (pt) Polipeptidos monopegilados no terminal-n e metodo para a sua preparacao
NO941681D0 (no) Humane IL-4 mutant proteiner
ATE198624T1 (de) Expression von albumin in hefe
DE3688038D1 (de) Verwendung von buspiron zur herstellung von pharmazeutischen zusammensetzungen zur linderung von krankhaften angst.
ATE170192T1 (de) Zusammensetzungen und methoden zur synthese des b-rezeptors für das natriuretische protein und verwendungsmethoden
DK0609280T3 (da) Humane IL-3 varianter
DK0851926T3 (da) Varianter af humant rekombinant gamminterferon (rhu-IFN-gamma) med forøget termisk stabilitet
ZA9510295B (en) Novel dipeptide p-amidinobenzylamides with n-terminal sulfonyl or aminosulfonyl radicals
ATE275968T1 (de) Mitteln zur behandlung von auto-immun krankheiten
ATE204021T1 (de) Klonierung, expression und charakterisierung einer neuen form der phosphatidylinositol-3- kinase
FI893681A0 (fi) N-2,3-butadienyltri- och tetra-aminoalkanderivat.
DE69002946D1 (de) Paracetamol enthaltende arzneizubereitung.
KR950702207A (ko) Tlp 복합체에 대한 항원성 부위와 이의 항체(antigenic regions of tumour-liberated particles (tlp) complexes and antibodies against them)
ATE123056T1 (de) Ancrod-proteine, ihre herstellung und verwendung.
ATE175971T1 (de) Wasserlösliche retinoide
PL309339A1 (en) Novel triazoquinazolines, methods of obtaining them and their application

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application